Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages

2015/08/31 by Stefano Ugel, Francesco De Sanctis, Susanna Mandruzzato +1 · 563 citations
Immunology and Microbiology · Medicine · #Angiogenesis #Biology #Cancer #Cancer Cells and Metastasis #Cancer Immunotherapy and Biomarkers #Cancer research #Cell biology #Haematopoiesis #Immune cells in cancer #Immunology #Metastasis #Myeloid #Myeloid-derived Suppressor Cell #Myelopoiesis #Stem cell #Stromal cell #Suppressor #Tumor cells #Tumor microenvironment #Tumor progression

paper · pdf · doi:10.1172/jci80006

published in Journal of Clinical Investigation 125(9), 3365-3376 (American Society for Clinical Investigation)

openalex publication_date 2015/08/31 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31

Abstract

The generation of an inflammatory environment is favorable and often decisive for the growth of both primary tumors and metastases. Tumor cells either express membrane molecules or release tumor-derived soluble factors able to alter myelopoiesis. Tumor-reprogrammed myeloid cells not only create a tolerogenic environment by blocking T cell functions and proliferation, but also directly drive tumor growth by promoting cancer stemness, angiogenesis, stroma deposition, epithelial-to-mesenchymal transition, and metastasis formation. In this Review, we discuss the interplay between immunosuppressive and protumoral myeloid cells and detail their immune-regulatory mechanisms, the molecular pathways involved in their differentiation, as well as their potential role as prognostic and diagnostic biomarkers and prospective targets for innovative approaches to treat tumor-bearing hosts.

Cited by

• Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
• Tumor promoting role of anti-tumor macrophages in tumor microenvironment
• Targeting the tumor microenvironment in cholangiocarcinoma to improve immune checkpoint blockade: potential strategies and translational pre‐clinical models
• Features of IL-1β Secretion by Macrophages in Monocyte Culture in Colorectal Cancer
• Cancer immunotherapy: harnessing the immune system to battle cancer
• Cancer immunotherapy: harnessing the immune system to battle cancer. [europepmc]
• Immune suppressive mechanisms in the tumor microenvironment. [europepmc]
• IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. [europepmc]
• The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. [europepmc]
• Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. [europepmc]
• Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. [europepmc]
• Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. [europepmc]
• Exogenous lipid uptake induces metabolic and functional reprogramming of tumor-associated myeloid-derived suppressor cells. [europepmc]
• Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. [europepmc]
• Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy. [europepmc]
• Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). [europepmc]
• Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. [europepmc]
• Treg Cells Promote the SREBP1-Dependent Metabolic Fitness of Tumor-Promoting Macrophages via Repression of CD8 + T Cell-Derived Interferon-γ. [europepmc]
• β2 adrenergic receptor-mediated signaling regulates the immunosuppressive potential of myeloid-derived suppressor cells. [europepmc]
• High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. [europepmc]
• CCL2/CCR2 signaling in cancer pathogenesis. [europepmc]
• Myocardial infarction accelerates breast cancer via innate immune reprogramming. [europepmc]
• Mechanisms of Cancer Resistance to Immunotherapy. [europepmc]
• Understanding the tumor microenvironment for effective immunotherapy. [europepmc]
• Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages. [europepmc]
• Role of the CCL2-CCR2 signalling axis in cancer: Mechanisms and therapeutic targeting. [europepmc]
• Combination strategies to maximize the benefits of cancer immunotherapy. [europepmc]
• Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. [europepmc]
• Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. [europepmc]
• Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. [europepmc]

Related

• Myeloid-Derived Suppressor Cells: Facilitators of Cancer and Obesity-Induced Cancer
• Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer
• Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species
• Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism
• Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade